Skip to content

The Effect of Topical Tranexamic Acid in endoscopic sinus surgery

The Effect of Topical Tranexamic Acid on Bleeding Reduction during Functional Endoscopic Sinus Surgery in choronic rhinosinousitis patient

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180730040640N1
Enrollment
56
Registered
2018-09-30
Start date
2018-09-23
Completion date
Unknown
Last updated
2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding control and improvement of the quality of surgical field in sinus endoscopic surgery of those who need surgery that did not respond to drug therapy.. Chronic sinusitis, unspecified

Interventions

Intervention 1: Intervention group: a group of 56 patients with chronic rhinosinusitis, requiring sinus endoscopic surgery was obtained. For preoperation patient , a mesh soaked in a mixture of phenyl

Sponsors

Boushehr University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with chronic rhinosinusitis that don't not respond to drug therapy and require sinus surgery The age of the participant(s) must be between 18 and 60 years old The amount of hemoglobin of the participant should be above 10 g/dl the amount of Bleeding time (BT), Prothrombin time (PT), Partial thromboplastin time (PTT), International normalized Ratio (INR) should be normal in participants.

Exclusion criteria

Exclusion criteria: Participants with cardiovascular disorders. Participants who have coagulation disorders or who are taking anticoagulant medicines(drugs) Participants with inherited coagulation disorders such as thrombophilia. Participants with coagulation disorders history in the past. Participants who have a history (record) of allergy to any drug(s) in the past. Participants who have been suffering from renal deficiency in the past. Participants with cirrhosis. Participants with chronic diseases, such as diabetes and hypertension. Participants who are pregnant. participants with malignant nasal tumor. Color blindness

Design outcomes

Primary

MeasureTime frame
Bleeding during surgery. Timepoint: At 15th, 30th and 45th minute after intervention. Method of measurement: The Boezaart measuring scale.;Surgeon's satisfaction with quality of surgical field. Timepoint: At 15th, 30th and 45th minute after intervention. Method of measurement: Likert scale plan for satisfaction.

Secondary

MeasureTime frame
Blood pressure. Timepoint: every 15 minutes after start of surgery. Method of measurement: heart monitoring.;Bleeding volume. Timepoint: every 15 minutes after start of surgery. Method of measurement: suction device.;Pulse rate. Timepoint: every 15 minutes after start of surgery. Method of measurement: heart monitoring.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAllahkaram Akhlaghi

Boushehr University of Medical Sciences

Akhlaghidr@gmail.com+98 77 3484 3924

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026